ArticleThe journal of allergy and clinical immunology. Global2024

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.

Barbara Rewerska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.